NPS: FDA Approves Updated Labelling For Gattex To Include Long-term Benefits

By RTT News, 
A A A


(RTTNews.com) - NPS Pharmaceuticals, Inc. ( NPSP ) Monday said the U.S. Food and Drug Administration, or FDA, has approved the the changes to the labeling on the company's lead product Gattex to indicate the long-term benefits of the injection.

In a 2-year, open-label study study, patients taking Gattex, which is indicated for the treatment of adults with Short Bowel Syndrome, or SBS, who are dependent on parenteral support, for more than two years achieved clinically meaningful reductions in parenteral support requirements.

Thirteen out of eighty-eight patients achieved complete independence, NPS said in a statement.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com



This article appears in: News Headlines

Referenced Stocks: NPSP

RTT News


More from RTT News:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

44,190,970
  • $6.74 ▼ 4.40%
36,814,323
  • $3.375 ▼ 1.89%
24,849,224
  • $74.67 ▼ 0.69%
24,629,238
  • $98.1494 ▲ 0.49%
22,145,812
  • $55.7293 ▲ 2.78%
18,843,669
  • $74.96 ▲ 23.57%
18,618,292
  • $25.545 ▼ 0.95%
18,564,195
  • $15.475 ▼ 0.74%
As of 7/28/2014, 12:23 PM